Press release
Atopic Dermatitis Pipeline Outlook, FDA Approvals, Clinical Trials, and Companies 2024 (Updated)
Key Takeaways from the Atopic Dermatitis Pipeline Report
* DelveInsight's Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
* The leading companies working in the Atopic Dermatitis Market include Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
* Promising Atopic Dermatitis Pipeline Therapies in the various stages of development include Baricitinib, Topical corticosteroid, si-544, Lebrikizumab, MEDI9929, and others.
* May 2024- Apogee Therapeutics Inc.- A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis. This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A will evaluate the safety and efficacy of one induction dose regimen of APG777 compared to placebo. In addition, two maintenance regimens will be evaluated in Part A. Part B will evaluate the benefit-risk of 3 dose regimens of APG777 compared to placebo.
* May 2024:- Incyte Corporation- A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis. This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
* May 2024:- Amgen- A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO). The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Request a sample and discover the recent advances in Atopic Dermatitis Treatment Drugs @ Atopic Dermatitis Pipeline Report [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
In the Atopic Dermatitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Atopic Dermatitis Overview
Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word 'dermatitis,' 'derm' means 'skin' and 'itis' means 'inflammation.' Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances.
Find out more about Atopic Dermatitis Therapeutics Assessment @ Atopic Dermatitis Preclinical and Discovery Stage Products [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Atopic Dermatitis Emerging Drugs Profile
* Tapinarof: Dermavant Sciences
* Etrasimod: Pfizer
* B244: AOBiome
* Lirentelimab: Allakos Inc.
* QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the Atopic Dermatitis therapies. The Atopic Dermatitis companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. phase III include, Dermavant Sciences.
DelveInsight's Atopic Dermatitis pipeline report covers around 110+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Atopic Dermatitis Pipeline Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Learn more about the emerging Atopic Dermatitis Pipeline Therapies @ Atopic Dermatitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Atopic Dermatitis Pipeline Report
* Coverage- Global
* Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Atopic Dermatitis Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
* Atopic Dermatitis Pipeline Therapies- Baricitinib, Topical corticosteroid, si-544, Lebrikizumab, MEDI9929, and others.
Dive deep into rich insights for new drugs for Atopic Dermatitis Treatment, Visit @ Atopic Dermatitis Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Atopic Dermatitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Atopic Dermatitis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Tapinarof: Dermavant Sciences
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* B244: AOBiome
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* EP262: Escient Pharmaceuticals
* Drug profiles in the detailed report.....
* Inactive Products
* Atopic Dermatitis Key Companies
* Atopic Dermatitis Key Products
* Atopic Dermatitis- Unmet Needs
* Atopic Dermatitis- Market Drivers and Barriers
* Atopic Dermatitis- Future Perspectives and Conclusion
* Atopic Dermatitis Analyst Views
* Atopic Dermatitis Key Companies
* Appendix
For further information on the Atopic Dermatitis Pipeline therapeutics, reach out to Atopic Dermatitis Unmet Needs and Analyst Views [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atopic-dermatitis-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Pipeline Outlook, FDA Approvals, Clinical Trials, and Companies 2024 (Updated) here
News-ID: 3487981 • Views: …
More Releases from ABNewswire
Tidy Hands Marks Five-Star Milestone with Over 500 Verified Reviews Among Cleane …
Tidy Hands Cleaners reaches 500+ verified five-star reviews, highlighting years of reliable house cleaning services for Austin homes and businesses with trained staff and satisfaction guarantees.
Cleaners Austin [https://www.google.com/search?&oq=cleaners+austin&kgmid=/g/11rd_gyrq3] residents rely on must deliver consistency, trust, and attention to detail-and reaching 500 verified five-star reviews proves Tidy Hands Cleaners has done exactly that. The company has achieved this milestone through years of dedicated service to Austin-area homes and businesses. The company's…
Custom T-Shirt Company Hi-Def Printing Transforms Cape Coral's Apparel Landscape …
Hi-Def Printing brings 40+ years of expertise to Cape Coral's apparel industry, offering professional screen printing and embroidery services for businesses, government agencies, and corporations across multiple sectors.
Custom t-shirt company Hi-Def Printing [https://www.google.com/maps/place/HI-DEF+PRINTING/@26.6337958,-81.9530357,1120m/data=!3m2!1e3!4b1!4m6!3m5!1s0x88db3f56d1dfccfb:0x718a1acdcb459667!8m2!3d26.6337958!4d-81.9530357!16s%2Fg%2F1w6r92d5!5m1!1e1?entry=ttu&g_ep=EgoyMDI1MTIwMi4wIKXMDSoASAFQAw%3D%3D] has become a driving force in Cape Coral's apparel decoration industry through its continued expansion of services. The business has been setting new standards for quality and customer service in Southwest Florida's wholesale apparel market. With over…
All Things Fresh Mobile Car Detailing Announces Mobile Car Detailing Tampa Expan …
All Things Fresh Mobile Car Detailing expands to Tampa Bay, offering eco-friendly mobile services with certified detailers, water-saving technology, and a 100% satisfaction guarantee for convenient at-home vehicle care.
All Things Fresh Mobile Car Detailing [https://www.google.com/maps/place/All+Things+Fresh+Mobile+Car+Detailing/@27.962817,-82.463724,35405m/data=!3m2!1e3!4b1!4m6!3m5!1s0xa2d8388de46e96bb:0xd412b647e54ac1bd!8m2!3d27.962817!4d-82.463724!16s%2Fg%2F11x7b6zsf1!5m1!1e1?entry=ttu&g_ep=EgoyMDI1MTIwMi4wIKXMDSoASAFQAw%3D%3D], a professional auto care provider established in 2017, has officially expanded operations into the Tampa Bay market. The company brings its signature eco-conscious approach and convenience-focused business model to Florida residents seeking professional mobile car…
All Day Roofing & More Expands Service Team to Meet Growing Roofing Fairfax Dema …
All Day Roofing & More expands its Fairfax team to meet rising demand, offering faster scheduling and maintaining quality roofing, siding, and gutter services with a community-first approach.
Roofing Fairfax [https://www.google.com/search?&oq=roofing+fairfax&kgmid=/g/11sqqkc23w] homeowners have come to expect reliable, professional service, and All Day Roofing & More has announced the expansion of its service team to meet that demand. The roofing company Fairfax has added trained professionals to handle a growing volume of…
More Releases for Atopic
Rising Prevalence Of Atopic Dermatitis Is A Key Catalyst For The Growth Of The A …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Atopic Dermatitis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The scope of the atopic dermatitis market has experienced substantial expansion recently, projected to increase from $8.61 billion in 2024 to reach $9.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.7%;…
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
